INMUNE BIO, INC.

La Jolla, CA · Founded 2015 · CIK 0001711754 · Biotech · Public

XPro1595, a dominant-negative TNF inhibitor molecule for treatment-resistant depression

inmunebio.com →
Grants
$2.0M
2 awards
Sector median: 1
Raised
$8.0M
2 Form D · May 2019
89 months since last filing
Contracts
—
No federal contracts on record
Patents
17
0 granted · 17 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$3,340,000
Private capital raisedForm D · SEC$4,699,904
Federal grantDepartment of Health and Human Services · Phase II · Effects of the Next Generation TNF Inhibitor (XPro1595) on Inflammation-related Deficits in Reward Circuitry and Motivation in Depression$739,739
Federal grantDepartment of Health and Human Services · Phase II · Effects of the Next Generation TNF Inhibitor (XPro1595) on Inflammation-related Deficits in Reward Circuitry and Motivation in Depression$1,210,682
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2316Moleculin Biotech, Inc.—$6.0M
2317ProtoKinetix, Inc.—$3.8M
2318CERO THERAPEUTICS HOLDINGS, INC.—$16M
2319INMUNE BIO, INC.—$8.0M
2320ARUKA BIO, INC.—$3.6M
2321Genomics PLC——
2322Lennham Pharmaceuticals, Inc.—$3.5M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 8 related persons
  • J. GanjeiDirector
  • Scott JudaDirector
  • Terry KnappDirector
  • Mark LowdellDirector · Executive Officer
  • David MossDirector · Executive Officer
  • Timothy SchroederDirector
  • David SzymkowskiDirector
  • Raymond TesiDirector · Executive Officer

Patents

USPTO · 0 granted of 17
  • Method For Detecting Anti-drug Antibodies Against Self-assembling Trimeric Biologics Using An Affinity Capture Elution-protein A/g Assayapplication
  • Human T-cell Acute Lymphoblastic Leukemia Cell Line & Applications For Treating Cancerapplication
  • Treatment Of Non-alcoholic Steatohepatitisapplication
  • Compositions & Method Of Treating Epilepsy By Selective Sequestration Of Soluble Tnfapplication
  • Stable Bioconjugates Of Soluble Tnf Muteinsapplication
  • Bioconjugates Of Dominant Negative Tnfapplication
  • COMPOSITIONS COMPRISING POOLED hucMSCs FOR THERAPEUTIC USESapplication
  • Human T-cell Acute Lymphoblastic Leukemia Cell Line & Applications For Treating Cancerapplication
  • Compositions Comprising Dominant Negative Tnf Protein And Methods For Therapeutic Deliveryapplication
  • Biomarker Driven Methods For Treating Major Depressive Disorderapplication
  • Method For Treating Therapy-resistant MUC4+ Cancerapplication
  • Treatment Of Non-alcoholic Steatohepatitisapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.